ClinicalTrials.gg
Active, not recruitingNCT04770753Updated Oct 30, 2026Results posted

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)

A Phase 3 interventional study of Placebo Matching Mitapivat and Mitapivat in Non-Transfusion-dependent Alpha-Thalassemia and Non-Transfusion-dependent Beta-Thalassemia, sponsored by Agios Pharmaceuticals, Inc.. Active, not recruiting at 68 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Primary conditionbeta-ThalassemiaRegistry: ThalassemiaReclassifiedWhy we changed it
Registry
Thalassemia — the first condition term the registry derived for this study.
ClinicalTrials.gg
beta-Thalassemia
Why
  1. The study's listed conditions name beta-Thalassemia, a narrower term within Thalassemia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Agios Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
194
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 49 studies in beta-Thalassemia with a site in Italy — 8 open to participants now, 17 under way, 6 of them phase 3. beta-Thalassemia · Italy.

Enrollment
7th of 39
194 · median 55
Started
2021
with 4 others
Phase 3
11 of 49
3 open now
Primary completion
2023-11
later than 0 of 16 live
Registered
38th of 49
by date
Lead sponsor
2 of 49
Agios Pharmaceuticals, Inc.

Among the 49 studies in beta-Thalassemia with a site in Italy, this one is the 7th largest by enrollment of the 39 interventional ones that give a count, is one of 5 that started in 2021, is one of 11 in phase 3, reaches primary completion later than 0 of the 16 other live ones, and was the 38th registered.

beta-Thalassemia

294 studies on the registry are indexed under beta-Thalassemia; 69 are open to participants now.

Browse beta-Thalassemia studies →

Open to participants now

8 of the 49 studies in beta-Thalassemia with a site in Italy are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in beta-Thalassemia with a site in Italy, or all of them as a file.
02

Study summary

The primary purpose of this study was to compare the effect of mitapivat versus placebo on hemolytic anemia in participants with alpha- or beta-non-transfusion dependent thalassemia (NTDT).

Read the detailed description

The mitapivat group included 130 participants whereas the placebo group had 64 participants.

03

Conditions studied

  • Non-Transfusion-dependent Alpha-Thalassemia
  • Non-Transfusion-dependent Beta-Thalassemia

Browse trials for

04

In context

beta-Thalassemia Reclassified

294 studies on the registry are indexed under beta-Thalassemia; 69 are open to participants now.

This study's enrollment of 194 is above the median of 40 across 208 interventional studies indexed under beta-Thalassemia.

Browse beta-Thalassemia studies →

Lead sponsor

Agios Pharmaceuticals, Inc. is the lead sponsor of 52 studies on the registry; 6 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 4 (17%) have results posted.

Compared within beta-Thalassemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Thalassemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of thalassemia (β-thalassemia with or without α-globin gene mutations, E (HbE)/β-thalassemia, or α-thalassemia/hemoglobin H [HbH] disease) based on Hb electrophoresis, Hb high-performance liquid chromatography (HPLC)), and/or deoxyribonucleic acid (DNA) analysis;
  • Hb concentration ≤10.0 grams per deciliter (g/dL) (100.0 grams per liter [g/L]), based on an average of at least 2 Hb concentration measurements (separated by ≥7 days) collected during the Screening Period;
  • Non-transfusion-dependent, defined as ≤5 red blood cell (RBC) units during the 24-week period before randomization; and no RBC transfusions ≤8 weeks before providing and no RBC transfusions during the Screening Period;
  • If taking hydroxyurea, the hydroxyurea dose must be stable for ≥16 weeks before randomization;
  • Women of (WOCBP) must be abstinent of sexual activities that may result in pregnancy as part of their usual lifestyle or agree to use 2 forms of , one of which must be considered highly effective, from the time of providing informed consent, throughout the study, and for 28 days after the last dose of study drug. The second form of contraception can be an acceptable barrier method;
  • Written informed consent before any study-related procedures are conducted and willing to comply with all study procedures for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Pregnant, breastfeeding, or parturient
  • Documented history of homozygous or heterozygous sickle (HbS) or hemoglobin C (HbC);
  • Prior exposure to gene therapy or prior bone marrow or stem cell transplantation;
  • Currently receiving treatment with luspatercept; the last dose must have been administered ≥18 weeks before randomization;
  • Currently receiving treatment with hematopoietic stimulating agents; the last dose must have been administered ≥18 weeks before randomization;
  • History of , (active or treated) ≤5 years before providing ;
  • History of active and/or uncontrolled cardiac or pulmonary disease ≤6 months before providing informed consent, except for nonmelanomatous skin cancer in situ, cervical carcinoma in situ, or breast carcinoma in situ;
  • Hepatobiliary disorders;
  • Estimated \<45 milliliters per minute (mL/min)/1.73 m\^2 by Chronic Kidney Disease Epidemiology Collaboration creatinine equation;
  • Nonfasting triglycerides >440 milligrams per deciliter (mg/dL) (5 millimoles per liter [mmol/L]);
  • Active infection requiring systemic antimicrobial therapy at the time of providing informed consent;
  • Positive test for virus antibody (HCVAb) with evidence of active HCV infection, or positive test for surface antigen (HBsAg);
  • Positive test for (HIV)-1 antibody (Ab) or HIV-2 Ab;
  • History of major surgery (including splenectomy) ≤16 weeks before providing informed consent and/or a major surgical procedure planned during the study;
  • Current enrollment or past participation (≤12 weeks before administration of the first dose of study drug or a timeframe equivalent to 5 half-lives of the study drug, whichever is longer) in any other clinical study involving an investigational treatment or device;
  • Receiving strong /5 inhibitors that have not been stopped for ≥5 days or a timeframe equivalent to 5 half-lives (whichever is longer); or strong CYP3A4 inducers that have not been stopped for ≥4 weeks or a timeframe equivalent to 5 half-lives (whichever is longer), before randomization;
  • Receiving anabolic steroids that have not been stopped for at least 4 weeks before randomization. Testosterone replacement therapy to treat hypogonadism is allowed. The testosterone dose and preparation must be stable for ≥10 weeks before randomization;
  • Known allergy to mitapivat or its (microcrystalline cellulose, croscarmellose sodium, sodium stearyl fumarate, mannitol, and magnesium stearate, Opadry® II Blue [hypromellose, titanium dioxide, lactose monohydrate, triacetin, and FD\&C Blue #2]);
  • Any medical, hematological, psychological, or behavioral condition(s) or prior or current therapy that, in the opinion of the Investigator, may confer an unacceptable risk to participating in the study and/or could confound the interpretation of the study data Also excluded are:

    • Participants who are institutionalized by regulatory or court order
    • Participants with any condition(s) that could create undue influence (including but not limited to incarceration, involuntary psychiatric confinement, and financial or familial affiliation with the Investigator or Sponsor)
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
194 participants (actual)

Study arms

  • Experimental
    Mitapivat

    Mitapivat 100 milligrams (mg), orally, twice daily (BID) for 24 weeks in double blind (DB) period and for up to 5 years in open label extension (OLE) period.

    Drug: Mitapivat

  • Placebo comparator
    Placebo

    Placebo matching mitapivat, orally, BID for 24 weeks in double blind period followed by Mitapivat 100 mg, orally, BID for up to 5 years in open label extension period.

    Drug: Placebo Matching Mitapivat · Drug: Mitapivat

Interventions

  • DrugPlacebo Matching Mitapivat

    Tablets

  • Tablets

    Also known as: AG-348, AG-348 sulfate hydrate, Mitapivat sulfate

07

What researchers measure

Primary outcomes

  1. Double-Blind Period: Percentage of Participants Who Achieved Hemoglobin (Hb) Response From Week 12 Through Week 24 Compared With Baseline

    Hb response is defined as ≥10 grams/ liter (g/L) (1.0 gram per deciliter) (g/dL) increase in average Hb concentration from Week 12 through Week 24 compared with baseline. Hb response was tested using the Mantel-Haenszel stratum weighted method adjusting for randomization stratification factors. Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.

    Time frame: Double-Blind Period: Baseline up to Week 12 through Week 24

Secondary outcomes

  1. Double-Blind Period: Change From Baseline in Average Functional Assessment of Chronic Illness Therapy (FACIT) -Fatigue Subscale Score From Week 12 Through Week 24

    The FACIT-Fatigue subscale includes a 13-item self-reported fatigue subscale, which assesses the severity and impact of fatigue (including the impact on daily activities and functioning).The FACIT-Fatigue subscale is scored on a 5-point Likert scale: 0 (not at all) to 4 (very much). The total FACIT-Fatigue subscale score ranges from 0 to 52, with a higher score indicating better health-related quality of life (HRQOL). Baseline is defined as the last assessment before randomization for subjects randomized and not dosed or the last assessment before start of study treatment for subjects randomized and dosed.

    Time frame: Double-Blind Period: Baseline, Week 12 through Week 24

  2. Double-Blind Period: Change From Baseline in Average Hb Concentration From Week 12 Through Week 24

    Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.

    Time frame: Double-Blind Period: Baseline, Week 12 through Week 24

  3. Double-Blind Period: Percentage of Participants Who Achieved Hb 1.5+ Response From Week 12 Through Week 24 Compared With Baseline

    Hb 1.5+ response is defined as a ≥1.5 g/dL increase in average Hb concentration from Week 12 through Week 24 compared with baseline. Hb 1.5+ response will be summarized using the Mantel-Haenszel stratum weighted method adjusting for randomization stratification factors. Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.

    Time frame: Double-Blind Period: Baseline up to Week 12 through Week 24

  4. Double-Blind Period: Change From Baseline in Indirect Bilirubin at Week 24

    Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.

    Time frame: Double-Blind Period: Baseline, Week 24

  5. Double-Blind Period: Change From Baseline in Lactate Dehydrogenase (LDH) at Week 24

    Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.

    Time frame: Double-Blind Period: Baseline, Week 24

  6. Double-Blind Period: Change From Baseline in Haptoglobin at Week 24

    Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.

    Time frame: Double-Blind Period: Baseline, Week 24

  7. Double-Blind Period: Change From Baseline in Reticulocytes at Week 24

    Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.

    Time frame: Double-Blind Period: Baseline, Week 24

  8. Double-Blind Period: Change From Baseline in Erythropoietin at Week 24

    Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.

    Time frame: Double-Blind Period: Baseline, Week 24

  9. Double-Blind Period: Percentage of Participants Who Achieved Patient Global Impression of Severity (PGIS)- Fatigue Response at Weeks 12, 16, 20, and 24

    PGIS-Fatigue measured participants' perception of their fatigue severity (7-day recall) on a 4-point scale ranging from '1=none' to '4=severe'. A participant was considered to have achieved the PGIS-Fatigue response at Weeks 12, 16, 20, or 24, if their baseline to postbaseline score met one of the following conditions: 'none' at baseline to 'none' postbaseline; 'mild' to 'mild' or 'none'; 'moderate' to 'mild' or 'none'; or 'severe' to 'moderate', 'mild', or 'none'.

    Time frame: Double-Blind Period: At Weeks 12, 16, 20, and 24

  10. Double-Blind Period: Percentage of Participants Who Achieved the Patient Global Impression of Change (PGIC)- Fatigue Response at Weeks 12, 16, 20, and 24

    The PGIC-Fatigue assesses change over time compared with baseline on a 5-point scale ranging from 0 to 4 where 0 indicates Much better and 4 as Much worse. A participant was considered to have achieved the PGIC-Fatigue response at Weeks 12, 16, 20, or 24 if their baseline PGIS and corresponding PGIC met one of the following conditions: if the PGIS at baseline was 'none' or 'mild' and PGIC at the visit was 'no change', 'a little better', or 'much better'; or if the PGIS at baseline was 'moderate' or 'severe' and PGIC at the visit was 'a little better' or 'much better'.

    Time frame: Double-Blind Period: At Weeks 12, 16, 20, and 24

  11. Double-Blind Period: Change From Baseline in the 6-minute Walk Test (6MWT) Distance at Week 24

    The 6MWT is a well-established performance outcome (PerfO) measure that is widely used to evaluate physical activity in terms of distance walked in patients with a variety of conditions. The test measures the distance an individual can walk on a hard, flat surface in 6 minutes.

    Time frame: Double-Blind Period: Baseline, Week 24

  12. Double-Blind Period: Change From Baseline in Serum Ferritin at Week 24

    Iron metabolism was assessed based on serum ferritin levels.

    Time frame: Double-Blind Period: Baseline, Week 24

  13. Double-Blind Period: Change From Baseline in Transferrin Saturation (TSAT) at Week 24

    Iron metabolism was assessed based on TSAT levels. Transferrin saturation is reported by dividing value of serum iron by total iron binding capacity.

    Time frame: Double-Blind Period: Baseline, Week 24

  14. Double-Blind Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Related TEAEs and TEAEs With Severity Greater Than or Equal to Grade 3

    AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the study drug. A serious adverse event (SAE) is any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs are AEs with an initial onset date during the on-treatment period or worsening from baseline and includes both serious \& non-serious TEAEs. Severity of AEs was evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; Version 4.03): grade 1: mild; grade 2: moderate; grade 3: severe or medically significant but not immediately life-threatening; grade 4: life threatening or disabling; grade 5: death related to AE.

    Time frame: Double-Blind Period: From the time of signing informed consent to Week 24

  15. Double-Blind Period: Plasma Concentration of Mitapivat

    Time frame: Double-Blind Period: Pre-dose at Week 12; pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 20

  16. Double-Blind Period: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-last) of Mitapivat

    Area under the concentration-time curve from time zero to Tlast on dosing day, calculated using the linear-log trapezoidal rule.

    Time frame: Double-Blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 20

  17. Double-Blind Period: Time of Last Quantifiable Concentration (Tlast) of Mitapivat

    Time frame: Double-Blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 20

  18. Double-Blind Period: Maximum Observed Plasma Concentration (Cmax) of Mitapivat

    Time frame: Double-Blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 20

  19. Double-Blind Period: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Mitapivat

    Time frame: Double-Blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 20

  20. Double-Blind Period: Last Quantifiable Plasma Concentration (Clast) of Mitapivat

    Time frame: Double-Blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 20

  21. Double-Blind Period: Blood Concentration of Adenosine Triphosphate (ATP)

    Time frame: Double-Blind Period: Pre-dose at Day 1; pre-dose at Week 12; pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 20

  22. Double-Blind Period: Blood Concentration of 2,3 - Diphosphoglycerate (2,3-DPG)

    Time frame: Double-Blind Period: Pre-dose at Day 1; pre-dose at Week 12; pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 20

  23. Open-Label Extension Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Related TEAEs and TEAEs With Severity of Greater Than or Equal to Grade 3

    AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the study drug. A serious adverse event (SAE) is any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs are AEs with an initial onset date during the on-treatment period or worsening from baseline and includes both serious \& non-serious TEAEs. Severity of abnormalities was evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; Version 4.03): grade 1: mild; grade 2: moderate; grade 3: severe or medically significant but not immediately life-threatening; grade 4: life threatening or disabling; grade 5: death related to AE.

    Time frame: Open-Label Extension Period: From week 24 up to end of study (approximately 5 years)

08

Results

Posted Jan 24, 2025

Participant flow

Participants took part in study at study sites in the United States of America, Brazil, Bulgaria, Canada, Denmark, France, Greece, Italy, Lebanon, Malaysia, Netherlands, Saudi Arabia, Spain, Taiwan, Thailand, Turkey, United Arab Emirates and the United Kingdom. Results are reported for 24-week DB period until primary completion date. Analysis of data for OLE period is still ongoing with anticipated completion in December 2028. Results for OLE period will be reported by December 2029.

Participant flow — Overall Study
MilestoneMitapivatPlacebo
Started13064
Treated12963
Completed12262
Not completed82
Withdrew: Randomized, never treated11
Withdrew: Withdrawal by subject31
Withdrew: Adverse event20
Withdrew: Pregnancy10
Withdrew: Other un-specified10

Outcome measures

PrimaryDouble-Blind Period: Percentage of Participants Who Achieved Hemoglobin (Hb) Response From Week 12 Through Week 24 Compared With Baseline

Hb response is defined as ≥10 grams/ liter (g/L) (1.0 gram per deciliter) (g/dL) increase in average Hb concentration from Week 12 through Week 24 compared with baseline. Hb response was tested using the Mantel-Haenszel stratum weighted method adjusting for randomization stratification factors. Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.

Time frame:
Double-Blind Period: Baseline up to Week 12 through Week 24
Reported as:
Number · Percentage of participants
Double-Blind Period: Percentage of Participants Who Achieved Hemoglobin (Hb) Response From Week 12 Through Week 24 Compared With Baseline
Percentage of participantsMitapivatPlacebo
Double-Blind Period: Percentage of Participants Who Achieved Hemoglobin (Hb) Response From Week 12 Through Week 24 Compared With Baseline42.31.6
Statistical analysis
  • Mitapivat vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Percentage difference: 40.9 · 95% CI 32.0 to 49.8
SecondaryDouble-Blind Period: Change From Baseline in Average Functional Assessment of Chronic Illness Therapy (FACIT) -Fatigue Subscale Score From Week 12 Through Week 24

The FACIT-Fatigue subscale includes a 13-item self-reported fatigue subscale, which assesses the severity and impact of fatigue (including the impact on daily activities and functioning).The FACIT-Fatigue subscale is scored on a 5-point Likert scale: 0 (not at all) to 4 (very much). The total FACIT-Fatigue subscale score ranges from 0 to 52, with a higher score indicating better health-related quality of life (HRQOL). Baseline is defined as the last assessment before randomization for subjects randomized and not dosed or the last assessment before start of study treatment for subjects randomized and dosed.

Time frame:
Double-Blind Period: Baseline, Week 12 through Week 24
Reported as:
Least squares mean · score on a scale
Double-Blind Period: Change From Baseline in Average Functional Assessment of Chronic Illness Therapy (FACIT) -Fatigue Subscale Score From Week 12 Through Week 24
score on a scaleMitapivatPlacebo
Double-Blind Period: Change From Baseline in Average Functional Assessment of Chronic Illness Therapy (FACIT) -Fatigue Subscale Score From Week 12 Through Week 244.85 ± 0.7321.46 ± 0.955
Statistical analysis
  • Mitapivat vs Placebo · ANCOVA · p = 0.0026 · Difference in lean square (ls) mean: 3.40 · 95% CI 1.21 to 5.59
SecondaryDouble-Blind Period: Change From Baseline in Average Hb Concentration From Week 12 Through Week 24

Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.

Time frame:
Double-Blind Period: Baseline, Week 12 through Week 24
Reported as:
Least squares mean · Gram per Liter (g/L)
Double-Blind Period: Change From Baseline in Average Hb Concentration From Week 12 Through Week 24
Gram per Liter (g/L)MitapivatPlacebo
Double-Blind Period: Change From Baseline in Average Hb Concentration From Week 12 Through Week 248.57 ± 0.666-1.06 ± 0.867
Statistical analysis
  • Mitapivat vs Placebo · ANCOVA · p = <0.0001 · Difference in ls mean: 9.63 · 95% CI 7.80 to 11.46
SecondaryDouble-Blind Period: Percentage of Participants Who Achieved Hb 1.5+ Response From Week 12 Through Week 24 Compared With Baseline

Hb 1.5+ response is defined as a ≥1.5 g/dL increase in average Hb concentration from Week 12 through Week 24 compared with baseline. Hb 1.5+ response will be summarized using the Mantel-Haenszel stratum weighted method adjusting for randomization stratification factors. Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.

Time frame:
Double-Blind Period: Baseline up to Week 12 through Week 24
Reported as:
Number · Percentage of participants
Double-Blind Period: Percentage of Participants Who Achieved Hb 1.5+ Response From Week 12 Through Week 24 Compared With Baseline
Percentage of participantsMitapivatPlacebo
Double-Blind Period: Percentage of Participants Who Achieved Hb 1.5+ Response From Week 12 Through Week 24 Compared With Baseline24.60
SecondaryDouble-Blind Period: Change From Baseline in Indirect Bilirubin at Week 24

Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.

Time frame:
Double-Blind Period: Baseline, Week 24
Reported as:
Least squares mean · Micromole per Liter (umol/L)
Double-Blind Period: Change From Baseline in Indirect Bilirubin at Week 24
Micromole per Liter (umol/L)MitapivatPlacebo
Double-Blind Period: Change From Baseline in Indirect Bilirubin at Week 24-10.65 ± 1.047-0.03 ± 1.403
SecondaryDouble-Blind Period: Change From Baseline in Lactate Dehydrogenase (LDH) at Week 24

Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.

Time frame:
Double-Blind Period: Baseline, Week 24
Reported as:
Least squares mean · Units per Liter (U/L)
Double-Blind Period: Change From Baseline in Lactate Dehydrogenase (LDH) at Week 24
Units per Liter (U/L)MitapivatPlacebo
Double-Blind Period: Change From Baseline in Lactate Dehydrogenase (LDH) at Week 24-30.07 ± 7.131-5.79 ± 9.440
SecondaryDouble-Blind Period: Change From Baseline in Haptoglobin at Week 24

Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.

Time frame:
Double-Blind Period: Baseline, Week 24
Reported as:
Least squares mean · Gram per Liter (g/L)
Double-Blind Period: Change From Baseline in Haptoglobin at Week 24
Gram per Liter (g/L)MitapivatPlacebo
Double-Blind Period: Change From Baseline in Haptoglobin at Week 24-0.002 ± 0.01450.017 ± 0.0199
SecondaryDouble-Blind Period: Change From Baseline in Reticulocytes at Week 24

Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.

Time frame:
Double-Blind Period: Baseline, Week 24
Reported as:
Least squares mean · 10^9 cells per liter (10^9 cells/L)
Double-Blind Period: Change From Baseline in Reticulocytes at Week 24
10^9 cells per liter (10^9 cells/L)MitapivatPlacebo
Double-Blind Period: Change From Baseline in Reticulocytes at Week 24-32.11 ± 10.600-14.74 ± 14.932
SecondaryDouble-Blind Period: Change From Baseline in Erythropoietin at Week 24

Baseline is defined as the average of all assessments within 42 days before randomization for subjects randomized and not dosed or within 42 days before the start of study treatment for subjects randomized and dosed.

Time frame:
Double-Blind Period: Baseline, Week 24
Reported as:
Least squares mean · International units per Liter (IU/L)
Double-Blind Period: Change From Baseline in Erythropoietin at Week 24
International units per Liter (IU/L)MitapivatPlacebo
Double-Blind Period: Change From Baseline in Erythropoietin at Week 2419.21 ± 37.773115.71 ± 49.413
SecondaryDouble-Blind Period: Percentage of Participants Who Achieved Patient Global Impression of Severity (PGIS)- Fatigue Response at Weeks 12, 16, 20, and 24

PGIS-Fatigue measured participants' perception of their fatigue severity (7-day recall) on a 4-point scale ranging from '1=none' to '4=severe'. A participant was considered to have achieved the PGIS-Fatigue response at Weeks 12, 16, 20, or 24, if their baseline to postbaseline score met one of the following conditions: 'none' at baseline to 'none' postbaseline; 'mild' to 'mild' or 'none'; 'moderate' to 'mild' or 'none'; or 'severe' to 'moderate', 'mild', or 'none'.

Time frame:
Double-Blind Period: At Weeks 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Double-Blind Period: Percentage of Participants Who Achieved Patient Global Impression of Severity (PGIS)- Fatigue Response at Weeks 12, 16, 20, and 24
percentage of participantsMitapivatPlacebo
At Week 1265.446.9
At Week 1663.142.2
At Week 2061.548.4
At Week 2462.346.9
SecondaryDouble-Blind Period: Percentage of Participants Who Achieved the Patient Global Impression of Change (PGIC)- Fatigue Response at Weeks 12, 16, 20, and 24

The PGIC-Fatigue assesses change over time compared with baseline on a 5-point scale ranging from 0 to 4 where 0 indicates Much better and 4 as Much worse. A participant was considered to have achieved the PGIC-Fatigue response at Weeks 12, 16, 20, or 24 if their baseline PGIS and corresponding PGIC met one of the following conditions: if the PGIS at baseline was 'none' or 'mild' and PGIC at the visit was 'no change', 'a little better', or 'much better'; or if the PGIS at baseline was 'moderate' or 'severe' and PGIC at the visit was 'a little better' or 'much better'.

Time frame:
Double-Blind Period: At Weeks 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Double-Blind Period: Percentage of Participants Who Achieved the Patient Global Impression of Change (PGIC)- Fatigue Response at Weeks 12, 16, 20, and 24
percentage of participantsMitapivatPlacebo
At Week 1271.553.1
At Week 1671.550.0
At Week 2066.256.3
At Week 2466.253.1
SecondaryDouble-Blind Period: Change From Baseline in the 6-minute Walk Test (6MWT) Distance at Week 24

The 6MWT is a well-established performance outcome (PerfO) measure that is widely used to evaluate physical activity in terms of distance walked in patients with a variety of conditions. The test measures the distance an individual can walk on a hard, flat surface in 6 minutes.

Time frame:
Double-Blind Period: Baseline, Week 24
Reported as:
Least squares mean · Meters
Double-Blind Period: Change From Baseline in the 6-minute Walk Test (6MWT) Distance at Week 24
MetersMitapivatPlacebo
Double-Blind Period: Change From Baseline in the 6-minute Walk Test (6MWT) Distance at Week 2430.48 ± 5.6517.11 ± 7.346
SecondaryDouble-Blind Period: Change From Baseline in Serum Ferritin at Week 24

Iron metabolism was assessed based on serum ferritin levels.

Time frame:
Double-Blind Period: Baseline, Week 24
Reported as:
Least squares mean · Microgram/Liter (mcg/L)
Double-Blind Period: Change From Baseline in Serum Ferritin at Week 24
Microgram/Liter (mcg/L)MitapivatPlacebo
Double-Blind Period: Change From Baseline in Serum Ferritin at Week 24-34.75 ± 32.710-32.48 ± 43.090
SecondaryDouble-Blind Period: Change From Baseline in Transferrin Saturation (TSAT) at Week 24

Iron metabolism was assessed based on TSAT levels. Transferrin saturation is reported by dividing value of serum iron by total iron binding capacity.

Time frame:
Double-Blind Period: Baseline, Week 24
Reported as:
Least squares mean · Ratio
Double-Blind Period: Change From Baseline in Transferrin Saturation (TSAT) at Week 24
RatioMitapivatPlacebo
Double-Blind Period: Change From Baseline in Transferrin Saturation (TSAT) at Week 24-0.029 ± 0.0212-0.047 ± 0.0262
SecondaryDouble-Blind Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Related TEAEs and TEAEs With Severity Greater Than or Equal to Grade 3

AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the study drug. A serious adverse event (SAE) is any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs are AEs with an initial onset date during the on-treatment period or worsening from baseline and includes both serious \& non-serious TEAEs. Severity of AEs was evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; Version 4.03): grade 1: mild; grade 2: moderate; grade 3: severe or medically significant but not immediately life-threatening; grade 4: life threatening or disabling; grade 5: death related to AE.

Time frame:
Double-Blind Period: From the time of signing informed consent to Week 24
Reported as:
Count of participants · Participants
Double-Blind Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Related TEAEs and TEAEs With Severity Greater Than or Equal to Grade 3
ParticipantsMitapivatPlacebo
Participants with TEAEs10750
Participants with Serious TEAEs80
Participants with TEAEs related to study drug5613
Participants with any TEAE of Grade ≥ 3182
SecondaryDouble-Blind Period: Plasma Concentration of Mitapivat
Time frame:
Double-Blind Period: Pre-dose at Week 12; pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 20
Reported as:
Mean · nanograms per milliliter (ng/mL)
Double-Blind Period: Plasma Concentration of Mitapivat
nanograms per milliliter (ng/mL)Mitapivat
Pre-dose at Week 1259.23 ± 51.081
Pre-dose at Week 2084.70 ± 138.852
30 Minutes Post-dose at Week 201209.00 ± 931.211
1 Hour Post-dose at Week 201386.35 ± 712.996
3 Hour Post-dose at Week 20740.26 ± 357.660
5 Hour Post-dose at Week 20359.42 ± 269.758
7 Hour Post-dose at Week 20206.82 ± 185.657
SecondaryDouble-Blind Period: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-last) of Mitapivat

Area under the concentration-time curve from time zero to Tlast on dosing day, calculated using the linear-log trapezoidal rule.

Time frame:
Double-Blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 20
Reported as:
Geometric mean · Hours*nanogram per milliliter (h*ng/mL)
Double-Blind Period: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-last) of Mitapivat
Hours*nanogram per milliliter (h*ng/mL)Mitapivat
Double-Blind Period: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-last) of Mitapivat4262.57 ± 31.4
SecondaryDouble-Blind Period: Time of Last Quantifiable Concentration (Tlast) of Mitapivat
Time frame:
Double-Blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 20
Reported as:
Median · hours
Double-Blind Period: Time of Last Quantifiable Concentration (Tlast) of Mitapivat
hoursMitapivat
Double-Blind Period: Time of Last Quantifiable Concentration (Tlast) of Mitapivat6.825 (6.50 to 7.42)
SecondaryDouble-Blind Period: Maximum Observed Plasma Concentration (Cmax) of Mitapivat
Time frame:
Double-Blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 20
Reported as:
Geometric mean · ng/mL
Double-Blind Period: Maximum Observed Plasma Concentration (Cmax) of Mitapivat
ng/mLMitapivat
Double-Blind Period: Maximum Observed Plasma Concentration (Cmax) of Mitapivat1565.69 ± 42.4
SecondaryDouble-Blind Period: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Mitapivat
Time frame:
Double-Blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 20
Reported as:
Median · Hours
Double-Blind Period: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Mitapivat
HoursMitapivat
Double-Blind Period: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Mitapivat1.000 (0.20 to 5.00)
SecondaryDouble-Blind Period: Last Quantifiable Plasma Concentration (Clast) of Mitapivat
Time frame:
Double-Blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 20
Reported as:
Geometric mean · ng/mL
Double-Blind Period: Last Quantifiable Plasma Concentration (Clast) of Mitapivat
ng/mLMitapivat
Double-Blind Period: Last Quantifiable Plasma Concentration (Clast) of Mitapivat166.93 ± 80.1
SecondaryDouble-Blind Period: Blood Concentration of Adenosine Triphosphate (ATP)
Time frame:
Double-Blind Period: Pre-dose at Day 1; pre-dose at Week 12; pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 20
Reported as:
Mean · microgram/milliliter (mcg/mL)
Double-Blind Period: Blood Concentration of Adenosine Triphosphate (ATP)
microgram/milliliter (mcg/mL)MitapivatPlacebo
At Pre-dose at Day 1180.87 ± 29.577184.91 ± 31.299
Pre-dose at Week 12242.07 ± 45.782176.81 ± 33.657
Pre-dose at Week 20235.79 ± 46.099168.10 ± 29.962
30 Minutes Post-dose at Week 20417.87 ± 102.853457.78 ± 89.932
1 Hour Post-dose at Week 20417.83 ± 105.752457.71 ± 104.431
3 Hour Post-dose at Week 20409.73 ± 96.379454.39 ± 107.966
5 Hour Post-dose at Week 20412.72 ± 94.150464.24 ± 97.007
7 Hour Post-dose at Week 20404.43 ± 97.586471.10 ± 113.165
SecondaryDouble-Blind Period: Blood Concentration of 2,3 - Diphosphoglycerate (2,3-DPG)
Time frame:
Double-Blind Period: Pre-dose at Day 1; pre-dose at Week 12; pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 20
Reported as:
Mean · mcg/mL
Double-Blind Period: Blood Concentration of 2,3 - Diphosphoglycerate (2,3-DPG)
mcg/mLMitapivatPlacebo
Pre-dose at Day 1526.40 ± 125.196506.14 ± 108.033
Pre-dose at Week 12434.90 ± 97.901497.68 ± 112.055
Pre-dose at Week 20426.30 ± 107.173468.22 ± 99.783
30 Minutes Post-dose at Week 20417.87 ± 102.853457.78 ± 89.932
1 Hour Post-dose at Week 20417.83 ± 105.752457.71 ± 104.431
3 Hour Post-dose at Week 20409.73 ± 96.379454.39 ± 107.966
5 Hour Post-dose at Week 20412.72 ± 94.150464.24 ± 97.007
7 Hour Post-dose at Week 20404.43 ± 97.586471.10 ± 113.165
SecondaryOpen-Label Extension Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Related TEAEs and TEAEs With Severity of Greater Than or Equal to Grade 3

AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the study drug. A serious adverse event (SAE) is any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs are AEs with an initial onset date during the on-treatment period or worsening from baseline and includes both serious \& non-serious TEAEs. Severity of abnormalities was evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; Version 4.03): grade 1: mild; grade 2: moderate; grade 3: severe or medically significant but not immediately life-threatening; grade 4: life threatening or disabling; grade 5: death related to AE.

Time frame:
Open-Label Extension Period: From week 24 up to end of study (approximately 5 years)

Results for this outcome have not been posted.

Adverse events

Collected over Double-blind period: From the time of signing informed consent to Week 24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mitapivat0/130 (0%)8/129 (6.2%)80/129 (62%)
Placebo0/64 (0%)0/63 (0%)33/63 (52.4%)
Most frequent serious events
Most frequent serious events
EventMitapivatPlacebo
Lower respiratory tract infectionInfections and infestations1/1290/63
PneumoniaInfections and infestations1/1290/63
Upper respiratory tract infectionInfections and infestations1/1290/63
Craniofacial fractureInjury, poisoning and procedural complications1/1290/63
Ulna fractureInjury, poisoning and procedural complications1/1290/63
AnaemiaBlood and lymphatic system disorders1/1290/63
Angina pectorisCardiac disorders1/1290/63
Abdominal painGastrointestinal disorders1/1290/63
Superficial vein thrombosisVascular disorders1/1290/63
Most frequent other events
Showing 10 of 15
Most frequent other events
EventMitapivatPlacebo
HeadacheNervous system disorders29/1296/63
Initial insomniaPsychiatric disorders18/1293/63
NauseaGastrointestinal disorders15/1295/63
Upper respiratory tract infectionInfections and infestations13/1294/63
InfluenzaInfections and infestations5/1296/63
DiarrhoeaGastrointestinal disorders11/1296/63
PyrexiaGeneral disorders4/1296/63
FatigueGeneral disorders12/1294/63
COVID-19Infections and infestations8/1295/63
Back painMusculoskeletal and connective tissue disorders3/1295/63

Baseline characteristics

Full Analysis Set (FAS) included all participants who were randomized.

Age, Continuous
Age, Continuous(years)MitapivatPlaceboTotal
Mean42.4 ± 13.0338.9 ± 12.9941.2 ± 13.09
Sex: Female, Male
Sex: Female, Male(Participants)MitapivatPlaceboTotal
Female8439123
Male462571
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MitapivatPlaceboTotal
Hispanic or Latino11617
Not Hispanic or Latino11858176
Unknown or Not Reported101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)MitapivatPlaceboTotal
White7336109
Asian522476
Black or African American112
American Indian or Alaska Native000
Native Hawaiian or Other Pacific Islander000
Multiracial101
Unknown224
Not reported112
09

Study locations

68 sites
10

References and documents

Publications

  • Taher AT, Al-Samkari H, Aydinok Y, Besser M, Boscoe AN, Dahlin JL, De Luna G, Estepp JH, Gheuens S, Gilroy KS, Glenthoj A, Sim Goh A, Iyer V, Kattamis A, Loggetto SR, Morris S, Musallam KM, Osman K, Ricchi P, Salido-Fierrez E, Sheth S, Tai F, Tevich H, Uhlig K, Urbstonaitis R, Viprakasit V, Cappellini MD, Kuo KHM; ENERGIZE investigators. Mitapivat in adults with non-transfusion-dependent alpha-thalassaemia or beta-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial. Lancet. 2025 Jul 5;406(10498):33-42. doi: 10.1016/S0140-6736(25)00635-X. Epub 2025 Jun 19. PubMed 40544857 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Nov 2023, 22 months.

Results were first posted in Jan 2025, 1 year 2 months after primary completion.

Of 18 phase 3 interventional studies under beta-Thalassemia, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2021
First posted
Feb 25, 2021
StartActual
Dec 20, 2021
Primary completionActual
Nov 13, 2023
CompletionEst.
Dec 2028
Results first posted
Jan 24, 2025
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
2 updates, last Oct 30, 2026
Show all 2 updates
  1. Oct 30, 2026
    Minor edits only
    + 1 other change: verification date
  2. Sep 28, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT04770753
Responsible party
Sponsor
First posted
Feb 25, 2021
Start date
Dec 20, 2021
Primary completion
Nov 13, 2023
Completion
Dec 2028 (estimated)
Results posted
Jan 24, 2025
Last update
Oct 30, 2026

Study contacts

Medical Affairs
study chair · Agios Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mitapivat

Start the discussion